|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sato K, Choyke PL and Kobayashi H:
Photoimmunotherapy of gastric cancer peritoneal carcinomatosis in a
mouse model. PLoS One. 9:e1132762014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wagner AD, Unverzagt S, Grothe W, Kleber
G, Grothey A, Haerting J and Fleig WE: Chemotherapy for advanced
gastric cancer. Cochrane Database Syst Rev. 17:CD0040642010.
|
|
4
|
Koizumi W, Narahara H, Hara T, Takagane A,
Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama
W, et al: S-1 plus cisplatin versus S-1 alone for first-line
treatment of advanced gastric cancer (SPIRITS trial): A phase III
trial. Lancet Oncol. 9:215–221. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Van Cutsem E, Moiseyenko VM, Tjulandin S,
Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi
E, et al: Phase III study of docetaxel and cisplatin plus
fluorouracil compared with cisplatin and fluorouracil as first-line
therapy for advanced gastric cancer: A report of the V325 Study
Group. J Clin Oncol. 24:4991–4997. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dank M, Zaluski J, Barone C, Valvere V,
Yalcin S, Peschel C, Wenczl M, Goker E, Cisar L, Wang K and Bugat
R: Randomized phase III study comparing irinotecan combined with
5-fluorouracil and folinic acid to cisplatin combined with
5-fluorouracil in chemotherapy naive patients with advanced
adenocarcinoma of the stomach or esophagogastric junction. Ann
Oncol. 19:1450–1457. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cunningham D, Starling N, Rao S, Iveson T,
Nicolson M, Coxon F, Middleton G, Daniel F, Oates J and Norman AR:
Upper Gastrointestinal Clinical Studies Group of the National
Cancer Research Institute of the United Kingdom: Capecitabine and
oxaliplatin for advanced esophagogastric cancer. N Engl J Med.
358:36–46. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tai W, Mahato R and Cheng K: The role of
HER2 in cancer therapy and targeted drug delivery. J Control
Release. 146:264–275. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lorenzen S and Lordick F: How will human
epidermal growth factor receptor 2-neu data impact clinical
management of gastric cancer? Curr Opin Oncol. 23:396–402. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fornaro L, Lucchesi M, Caparello C, Vasile
E, Caponi S, Ginocchi L, Masi G and Falcone A: Anti-HER agents in
gastric cancer: From bench to bedside. Nat Rev Gastroenterol
Hepatol. 8:369–383. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cid Pazo RA and Antón A: Advanced
HER2-positive gastric cancer: Current and future targeted
therapies. Crit Rev Oncol Hematol. 85:350–362. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shimoyama S: Unraveling trastuzumab and
lapatinib inefficiency in gastric cancer: Future steps (review).
Mol Clin Oncol. 2:175–181. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tyagi P and Santos JL: Macromolecule
nanotherapeutics: Approaches and challenges. Drug Discov Today. Jan
8–2018.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jain TK, Morales MA, Sahoo SK,
Leslie-Pelecky DL and Labhasetwar V: Iron oxide nanoparticles for
sustained delivery of anticancer agents. Mol Pharm. 2:194–205.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sun C, Lee JS and Zhang M: Magnetic
nanoparticles in MR imaging and drug delivery. Adv Drug Deliv Rev.
60:1252–1265. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kettering M, Zorn H, Bremer-Streck S,
Oehring H, Zeisberger M, Bergemann C, Hergt R, Halbhuber KJ, Kaiser
WA and Hilger I: Characterization of iron oxide nanoparticles
adsorbed with cisplatin for biomedical applications. Phys Med Biol.
54:5109–5121. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yang L, Mao H, Cao Z, Wang YA, Peng X,
Wang X, Sajja HK, Wang L, Duan H, Ni C, et al: Molecular imaging of
pancreatic cancer in an animal model using targeted multifunctional
nanoparticles. Gastroenterology. 136:1514–1525.e2. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Davis ME, Chen ZG and Shin DM:
Nanoparticle therapeutics: An emerging treatment modality for
cancer. Nat Rev Drug Discov. 7:771–782. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tong L, Zhao M, Zhu S and Chen J:
Synthesis and application of superparamagnetic iron oxide
nanoparticles in targeted therapy and imaging of cancer. Front Med.
5:379–387. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jain RK and Stylianopoulos T: Delivering
nanomedicine to solid tumors. Nat Rev Clin Oncol. 7:653–664. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fang J, Nakamura H and Maeda H: The EPR
effect: Unique features of tumor blood vessels for drug delivery,
factors involved, and limitations and augmentation of the effect.
Adv Drug Deliv Rev. 63:136–151. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Minchinton AI and Tannock IF: Drug
penetration in solid tumours. Nat Rev Cancer. 6:583–592. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xu C, Xie J, Ho D, Wang C, Kohler N, Walsh
EG, Morgan JR, Chin YE and Sun S: Au-Fe3O4 dumbbell nanoparticles
as dual-functional probes. Angew Chem Int Ed Engl. 47:173–176.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Stevens WC Jr and Hill DC: General methods
for flash chromatography using disposable columns. Mol Divers.
13:247–252. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Workman P, Aboagye EO, Balkwill F, Balmain
A, Bruder G, Chaplin DJ, Double JA, Everitt J, Farningham DA,
Glennie MJ, et al: Guidelines for the welfare and use of animals in
cancer research. Br J Cancer. 102:1555–1577. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gauduchon J, Gouilleux F, Maillard S,
Marsaud V, Renoir JM and Sola B: 4-Hydroxytamoxifen inhibits
proliferation of multiple myeloma cells in vitro through
down-regulation of c-Myc, up-regulation of p27Kip1, and modulation
of Bcl-2 family members. Clin Cancer Res. 11:2345–2354. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Imasaka T: Ultraviolet femtosecond laser
ionization mass spectrometry. Chem Rec. 8:23–32. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xu C, Wang B and Sun S: Dumbbell-like
Au-Fe3O4 nanoparticles for target-specific platin delivery. J Am
Chem Soc. 131:4216–4217. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cao Z, Zhu W, Wang W, Zhang C, Xu M, Liu
J, Feng ST, Jiang Q and Xie X: Stable cerasomes for simultaneous
drug delivery and magnetic resonance imaging. Int J Nanomedicine.
9:5103–5116. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hu Y, Mignani S, Majoral JP, Shen M and
Shi X: Construction of iron oxide nanoparticle-based hybrid
platforms for tumor imaging and therapy. Chem Soc Rev.
47:1874–1900. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kim J, Fox C, Peng S, Pusung M, Pectasides
E, Matthee E, Hong YS, Do IG, Jang J, Thorner AR, et al:
Preexisting oncogenic events impact trastuzumab sensitivity in
ERBB2-amplified gastroesophageal adenocarcinoma. J Clin Invest.
124:5145–5158. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Baselga J, Coleman RE, Cortés J and Janni
W: Advances in the management of HER2-positive early breast cancer.
Crit Rev Oncol Hematol. 119:113–122. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Schneider GF, Subr V, Ulbrich K and Decher
G: Multifunctional cytotoxic stealth nanoparticles. A model
approach with potential for cancer therapy. Nano Lett. 9:636–642.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Won E, Janjigian YJ and Ilson DH: HER2
directed therapy for gastric/esophageal cancers. Curr Treat Options
Oncol. 15:395–404. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Figueroa-Magalhães MC, Jelovac D, Connolly
RM and Wolff AC: Treatment of HER2-positive breast cancer. Breast.
23:128–136. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Riddell IA: Cisplatin and Oxaliplatin: Our
current understanding of their actions. Met Ions Life Sci. 18:pii.
2018.doi: 10.1515/9783110470734-007. PubMed/NCBI
|
|
37
|
Montagnani F, Turrisi G, Marinozzi C,
Aliberti C and Fiorentini G: Effectiveness and safety of
oxaliplatin compared to cisplatin for advanced, unresectable
gastric cancer: A systematic review and meta-analysis. Gastric
Cancer. 14:50–55. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Liu K, Chen H, You Q, Shi H and Wang Z:
The siRNA cocktail targeting VEGF and HER2 inhibition on the
proliferation and induced apoptosis of gastric cancer cell. Mol
Cell Biochem. 386:117–124. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang T, Zhao J, Ren JL, Zhang L, Wen WH,
Zhang R, Qin WW, Jia LT, Yao LB, Zhang YQ, et al: Recombinant
immunoproapoptotic proteins with furin site can translocate and
kill HER2-positive cancer cells. Cancer Res. 67:11830–11839. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang WJ, Lei YY, Mei JH and Wang CL:
Recent progress in HER2 associated breast cancer. Asian Pac J
Cancer Prev. 16:2591–2600. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Mar N, Vredenburgh JJ and Wasser JS:
Targeting HER2 in the treatment of non-small cell lung cancer. Lung
Cancer. 87:220–225. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Iqbal N and Iqbal N: Human epidermal
growth factor receptor 2 (HER2) in cancers: Overexpression and
therapeutic implications. Mol Biol Int. 2014:8527482014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Verma A, Uzun O, Hu Y, Hu Y, Han HS,
Watson N, Chen S, Irvine DJ and Stellacci F:
Surface-structure-regulated cell-membrane penetration by
monolayer-protected nanoparticles. Nat Mater. 7:588–595. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
López-Castro JD, Maraloiu AV, Delgado JJ,
Calvino JJ, Blanchin MG, Gálvez N and Domínguez-Vera JM: From
synthetic to natural nanoparticles: Monitoring the biodegradation
of SPIO (P904) into ferritin by electron microscopy. Nanoscale.
3:4597–4599. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Lunov O, Zablotskii V, Syrovets T, Röcker
C, Tron K, Nienhaus GU and Simmet T: Modeling receptor-mediated
endocytosis of polymer-functionalized iron oxide nanoparticles by
human macrophages. Biomaterials. 32:547–555. 2011. View Article : Google Scholar : PubMed/NCBI
|
